Biologic Therapies: Targeting Severe Asthma at the Molecular Level
DOI:
https://doi.org/10.12775/JEHS.2024.74.52570Keywords
biologic agents for asthma, omalizumab, mepolizumab, bernalizumab, tezepelumab, monoclonal antibodiesAbstract
Introduction:
Severe asthma is a chronic respiratory condition that affects a significant number of individuals, causing persistent inflammation of the airways and leading to recurrent symptoms such as wheezing, coughing, and shortness of breath. While conventional asthma treatments, including inhaled corticosteroids and bronchodilators, are generally effective for most asthma patients, they may not always provide sufficient relief for individuals with severe asthma. In such cases, the use of biologic agents licensed specifically for severe asthma can be a valuable treatment option.
Aim of the study:
This article aims to explore the different biologic agents licensed for severe asthma and delve into their effectiveness in managing this complex and challenging condition.
Material and methods:
Literature available in the PubMed database was reviewed using the following keywords: biologic agents for asthma; omalizumab; mepolizumab; bernalizumab; tezepelumab; monoclonal antibodies.
Conclusions:
These medications are designed to target the underlying mechanisms of severe asthma, addressing the root causes of the condition rather than just managing the symptoms. As a result, they have shown promising results in improving symptoms and reducing exacerbations in individuals with severe asthma. By understanding the potential benefits of these medications, healthcare professionals can make informed decisions when it comes to treating patients with severe asthma.
References
“Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.,” Lancet (London, England), vol. 390, no. 10100, pp. 1211–1259, Sep. 2017, doi: 10.1016/S0140-6736(17)32154-2.
“Global Initiative for Asthma. Global Strategy for Asthma Managment and Prevention, 2024. Updated May 2024. Available from: www.ginasthma.org.”
K. F. Chung et al., “International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma,” Eur. Respir. J., vol. 43, no. 2, pp. 343–373, Feb. 2014, doi: 10.1183/09031936.00202013.
M. Kupczyk et al., “Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma.,” Postep. dermatologii i Alergol., vol. 36, no. 2, pp. 147–157, Apr. 2019, doi: 10.5114/ada.2019.84591.
M. C. McGregor, J. G. Krings, P. Nair, and M. Castro, “Role of Biologics in Asthma.,” Am. J. Respir. Crit. Care Med., vol. 199, no. 4, pp. 433–445, Feb. 2019, doi: 10.1164/rccm.201810-1944CI.
K. F. Chung et al., “Characteristics, phenotypes, mechanisms and management of severe asthma.,” Chin. Med. J. (Engl)., vol. 135, no. 10, pp. 1141–1155, May 2022, doi: 10.1097/CM9.0000000000001990.
R. Nadif et al., “Heterogeneity of asthma according to blood inflammatory patterns.,” Thorax, vol. 64, no. 5, pp. 374–380, May 2009, doi: 10.1136/thx.2008.103069.
R. H. Green et al., “Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.,” Lancet (London, England), vol. 360, no. 9347, pp. 1715–1721, Nov. 2002, doi: 10.1016/S0140-6736(02)11679-5.
K. Rajewsky, “The advent and rise of monoclonal antibodies.,” Nature, vol. 575, no. 7781. England, pp. 47–49, Nov. 2019, doi: 10.1038/d41586-019-02840-w.
“Global Initiative for Asthma. Difficult-To-Treat & Severe Asthma in Adolescent and Adult Patients, 2023. Available from: www.ginasthma.org,” Gina. .
N. A. Gandhi, B. L. Bennett, N. M. H. Graham, G. Pirozzi, N. Stahl, and G. D. Yancopoulos, “Targeting key proximal drivers of type 2 inflammation in disease.,” Nat. Rev. Drug Discov., vol. 15, no. 1, pp. 35–50, Jan. 2016, doi: 10.1038/nrd4624.
A. B. Kay, “The role of T lymphocytes in asthma.,” Chem. Immunol. Allergy, vol. 91, pp. 59–75, 2006, doi: 10.1159/000090230.
P. Venkatesan, “2023 GINA report for asthma,” Lancet Respir. Med., vol. 11, no. 7, p. 589, Jul. 2023, doi: 10.1016/S2213-2600(23)00230-8.
C. Pelaia et al., “Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma,” Biomed Res. Int., vol. 2018, p. 4839230, 2018, doi: 10.1155/2018/4839230.
H. Harb and T. A. Chatila, “Mechanisms of Dupilumab.,” Clin. Exp. allergy J. Br. Soc. Allergy Clin. Immunol., vol. 50, no. 1, pp. 5–14, Jan. 2020, doi: 10.1111/cea.13491.
S. C. Kotoulas, I. Tsiouprou, E. Fouka, A. Pataka, D. Papakosta, and K. Porpodis, “Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma,” Journal of Personalized Medicine, vol. 12, no. 2. 2022, doi: 10.3390/jpm12020165.
K. Godse, A. Mehta, S. Patil, M. Gautam, and N. Nadkarni, “Omalizumab-A Review.,” Indian J. Dermatol., vol. 60, no. 4, pp. 381–384, 2015, doi: 10.4103/0019-5154.160490.
M. Castro et al., “Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.,” ERJ open Res., vol. 6, no. 1, Jan. 2020, doi: 10.1183/23120541.00204-2019.
M.-G. Andrew et al., “Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma,” N. Engl. J. Med., vol. 384, no. 19, pp. 1800–1809, May 2021, doi: 10.1056/NEJMoa2034975.
A. Menzies-Gow, M. E. Wechsler, and C. E. Brightling, “Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?,” Respir. Res., vol. 21, no. 1, p. 268, 2020, doi: 10.1186/s12931-020-01505-x.
J. E. Kavanagh, A. P. Hearn, and D. J. Jackson, “A pragmatic guide to choosing biologic therapies in severe asthma,” Breathe, vol. 17, no. 4, p. 210144, Dec. 2021, doi: 10.1183/20734735.0144-2021.
R. Normansell, S. Walker, S. J. Milan, E. H. Walters, and P. Nair, “Omalizumab for asthma in adults and children.,” Cochrane database Syst. Rev., vol. 2014, no. 1, p. CD003559, Jan. 2014, doi: 10.1002/14651858.CD003559.pub4.
D. J. Jackson et al., “Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study,” Lancet, vol. 403, no. 10423, pp. 271–281, Jan. 2024, doi: 10.1016/S0140-6736(23)02284-5.
L. Liu, P. Zhou, Z. Wang, S. Zhai, and W. Zhou, “Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.,” Frontiers in pediatrics, vol. 10. Switzerland, p. 851177, 2022, doi: 10.3389/fped.2022.851177.
I. Agache et al., “Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma,” Allergy, vol. 75, no. 5, pp. 1023–1042, May 2020, doi: https://doi.org/10.1111/all.14221.
J. W. Lanario, L. Cartwright, R. C. Jones, R. Sayers, M. E. Hyland, and M. Masoli, “‘Life-changing’: the experience of super-responders to biologics in severe asthma.,” BMC Pulm. Med., vol. 22, no. 1, p. 445, Nov. 2022, doi: 10.1186/s12890-022-02241-2.
B. Rogala et al., “Biological therapy of severe asthma – Position of Polish Society of Allergology and Polish Society of Respiratory Diseases,” Alergol. Pol. - Polish J. Allergol., vol. 10, no. 2, pp. 77–99, 2023, doi: 10.5114/pja.2023.129093.
O. Sardon-Prado, C. Diaz-Garcia, P. Corcuera-Elosegui, J. Korta-Murua, J. Valverde-Molina, and M. Sanchez-Solis, “Severe Asthma and Biological Therapies: Now and the Future.,” J. Clin. Med., vol. 12, no. 18, Sep. 2023, doi: 10.3390/jcm12185846.
R. S. J. Peebles and M. A. Aronica, “Proinflammatory Pathways in the Pathogenesis of Asthma.,” Clin. Chest Med., vol. 40, no. 1, pp. 29–50, Mar. 2019, doi: 10.1016/j.ccm.2018.10.014.
J. M. Knight et al., “Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease.,” J. Biol. Chem., vol. 293, no. 26, pp. 10026–10040, Jun. 2018, doi: 10.1074/jbc.RA117.000567.
J. Sun et al., “Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study.,” Front. Immunol., vol. 14, p. 1034755, 2023, doi: 10.3389/fimmu.2023.1034755.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kamila Szewczyk, Bartłomiej Szewczyk, Wiktoria Julia Krzesłowska, Paulina Pytel, Szymon Wiśniewski, Weronika Hołownia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 462
Number of citations: 0
